Comment from Prime Therapeutics

Summary: Prime Therapeutics LLC supports the FDA's efforts to create a streamlined pathway for individualized therapies but recommends providing more explicit guidance on submission requirements, data transparency, and post-marketing commitments. They also advocate for clear communication regarding variant expansion, the role of AI in data generation, and the development of payment models to balance financial risk between manufacturers and health plans.